계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
NeurogesX
About
NeurogesX develops and commercializes therapies for chronic peripheral neuropathic pain.
- 51 - 100
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $8.40M
- Industries
- Biotechnology,Medical,Medical Device,Neuroscience
- Founded date
- Jan 1, 1998
- Number Of Employee
- 51 - 100
- Operating Status
- Active
NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic pain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 1, 2005 | Series D | $20M | 1 | — | — | Detail |
| Feb 24, 2004 | Series C | $35M | 2 | — | — | Detail |
| Jan 23, 2002 | Series B | $22.86M | 1 | — | — | Detail |
| Jun 1, 2000 | Series A | $8.40M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series D |
Diamond Capital Management
|
— | Series C |
